Faculty

Back to Index
Alan L Epstein, MD, PhD
Professor of Pathology
Pathology
HMR 2011 Zonal Ave Health Sciences Campus Los Angeles
+1 323 442 1172

Overview

Alan L. Epstein MD, PhD is a Professor at the Keck School of Medicine at the University of Southern California and has over 30 years of experience in the laboratory developing monoclonal antibodies and other reagents for the treatment of cancer. He has published over 150 papers in the field and has filed 25 patents including those describing the use of TNT antibodies for the imaging and therapy of cancer. Along with TNT antibodies, Dr. Epstein has invented the Lym-1 antibody for the treatment of lymphoma, vasopermeability enhancing antibodies to increase the uptake of drugs and antibodies in tumors, the LN panel of diagnostic antibodies, and most recently several novel fusion proteins for the immunotherapy of cancer. He has been a consultant for numerous biotechnology companies and is an accomplished speaker and scientist in his field. Dr. Epstein holds a bachelor’s degree in biology from Wesleyan University, Middletown, CT and obtained the MD and PhD degrees from the Medical Scientist Training Program at Stanford University School of Medicine. Before coming to the University of Southern California, Dr. Epstein started his academic career in the Department of Medicine, Division of Medical Oncology at the Northwestern University School of Medicine in Chicago.

Publications

. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models Nat Commun. 2018 May 22; 9(1):2024. View in: PubMed

. IL-13 is produced by tumor cells in Breast Implant Associated Anaplastic Large Cell Lymphoma: implications for pathogenesis Hum Pathol. 2018 Apr 22. View in: PubMed

. Critical role of OX40 signaling in the TCR-independent phase of human and murine thymic Treg generation Cell Mol Immunol. 2018 Mar 26. View in: PubMed

. Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma Int J Mol Sci. 2017 Dec 20; 18(12). View in: PubMed

. Sci Rep. 2017 Jul 26; 7(1):6594. View in: PubMed

. Soluble OX40L and JAG1 Induce Selective Proliferation of Functional Regulatory T-Cells Independent of canonical TCR signaling Sci Rep. 2017 Jan 03; 7:39751. View in: PubMed

. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations Proc Natl Acad Sci U S A. 2017 04 11; 114(15):3975-3980. View in: PubMed

. Age-dependent divergent effects of OX40L treatment on the development of diabetes in NOD mice Autoimmunity. 2016 Aug; 49(5):298-311. View in: PubMed

. Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma Aesthet Surg J. 2016 Jul; 36(7):773-81. View in: PubMed

. Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models Cancer Immunol Immunother. 2016 May; 65(5):511-23. View in: PubMed

. Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent Thyroid. 2016 Mar; 26(3):381-9. View in: PubMed

. Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvant J Immunother Cancer. 2016; 4:11. View in: PubMed

. Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins J Immunol Res. 2016; 2016:2342187. View in: PubMed

. Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases Plast Reconstr Surg. 2015 Mar; 135(3):695-705. View in: PubMed

. Phase 1 Dose-Escalation Study with LEC/chTNT-3 and Toceranib Phosphate (Palladia®) in Dogs with Spontaneous Malignancies J Cancer Sci Ther. 2015; 7(6):167-174. View in: PubMed

. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro Clin Cancer Res. 2014 Dec 01; 20(23):6034-44. View in: PubMed

. Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA Expert Rev Anticancer Ther. 2014 Oct; 14(10):1243-9. View in: PubMed

. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration Thyroid. 2014 Sep; 24(9):1385-93. View in: PubMed

. Boron neutron capture therapy as new treatment for clear cell sarcoma: trial on different animal model Appl Radiat Isot. 2014 Jun; 88:59-63. View in: PubMed

. A hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibody ACS Nano. 2014 Mar 25; 8(3):2064-76. View in: PubMed

. CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma J Immunol. 2014 Jan 01; 192(1):224-33. View in: PubMed

. Cytoreductive chemotherapy improves the biodistribution of antibodies directed against tumor necrosis in murine solid tumor models Mol Cancer Ther. 2013 Dec; 12(12):2827-36. View in: PubMed

. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy J Immunother. 2013 Nov-Dec; 36(9):477-89. View in: PubMed

. Modulation of Treg cells/T effector function by GITR signaling is context-dependent Eur J Immunol. 2013 Sep; 43(9):2421-9. View in: PubMed

. Generation of tumor-targeted antibody-CpG conjugates J Immunol Methods. 2013 Mar 29; 389(1-2):45-51. View in: PubMed

. Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma Head Neck Oncol. 2013 Feb 27; 5(3):24. View in: PubMed

. Establishment and characterization of a new human extragonadal germ cell line, SEM-1, and its comparison with TCam-2 and JKT-1Urology. 2013 Feb; 81(2):464. e1-9. View in: PubMed

. An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas Clin Cancer Res. 2012 Sep 01; 18(17):4657-68. View in: PubMed

. Survival signals and targets for therapy in breast implant-associated ALK--anaplastic large cell lymphoma Clin Cancer Res. 2012 Sep 01; 18(17):4549-59. View in: PubMed

. The perichromatin region of the plant cell nucleus is the area with the strongest co-localisation of snRNA and SR proteins Planta. 2012 Aug; 236(2):715-26. View in: PubMed

. Unique approach for B lymphoma therapy Blood. 2012 Apr 19; 119(16):3647-8. View in: PubMed

. A rare case of noninsulinoma pancreatogenous hypoglycemia syndrome Case Rep Gastrointest Med. 2012; 2012:164305. View in: PubMed

. Exploring the Therapeutic Efficacy of Glioma Vaccines Based on Allo- and Syngeneic Antigens and Distinct Immunological Costimulation Activators J Clin Cell Immunol. 2012; Suppl 5:004. View in: PubMed

. Evaluation of BPA uptake in clear cell sarcoma (CCS) in vitro and development of an in vivo model of CCS for BNCT studies Appl Radiat Isot. 2011 Dec; 69(12):1713-6. View in: PubMed

. Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors Immunotherapy. 2011 Nov; 3(11):1317-40. View in: PubMed

. USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristics Oral Oncol. 2011 Sep; 47(9):810-7. View in: PubMed

. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines J Transl Med. 2011 Jun 09; 9:90. View in: PubMed

. A new mechanism for blocking myeloid-derived suppressor cells by CpG Clin Cancer Res. 2011 Apr 01; 17(7):1645-8. View in: PubMed

. Breast implant-associated, ALK-negative, T-cell, anaplastic, large-cell lymphoma: establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entity Cancer. 2011 Apr 01; 117(7):1478-89. View in: PubMed

. Rapidly fatal pulmonary fibrosis in a patient with psoriatic arthritis treated with adalimumab J Rheumatol. 2011 Feb; 38(2):398-9. View in: PubMed

. A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment Cancer Res. 2010 Nov 15; 70(22):9041-52. View in: PubMed

. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells J Immunol. 2010 Aug 15; 185(4):2273-84. View in: PubMed

. Establishment and characterization of a novel head and neck squamous cell carcinoma cell line USC-HN1 Head Neck Oncol. 2010 Feb 22; 2:5. View in: PubMed

. Target-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity J Immunol. 2009 May 01; 182(9):5430-8. View in: PubMed

. Influence of an educational seminar on use of disease activity measurements by rheumatologists in treatment of rheumatoid arthritis J Rheumatol. 2009 Mar; 36(3):532-8. View in: PubMed

. Immunogenicity of Iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients Cancer Immunol Immunother. 2008 May; 57(5):677-84. View in: PubMed

. Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models J Immunother. 2008 Apr; 31(3):235-45. View in: PubMed

. Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer Clin Cancer Res. 2008 Jan 15; 14(2):579-88. View in: PubMed

. Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy Clin Cancer Res. 2007 Jul 01; 13(13):4016-25. View in: PubMed

. Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumors Cancer Biother Radiopharm. 2007 Jun; 22(3):342-56. View in: PubMed

. RA8, a human anti-CD25 antibody against human Treg cells Hybridoma (Larchmt). 2007 Jun; 26(3):119-30. View in: PubMed

. Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines Leuk Lymphoma. 2007 May; 48(5):944-56. View in: PubMed

. Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors Clin Cancer Res. 2007 May 01; 13(9):2758-67. View in: PubMed

. Soluble Fc fusion proteins for biomedical research Methods Mol Biol. 2007; 378:33-52. View in: PubMed

. B71/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors. J Immunother. 2006 Jul-Aug; 29(4):425-35. View in: PubMed

. H60/TNT-3 fusion protein activates NK cells in vitro and improves immunotherapeutic outcome in murine syngeneic tumor models J Immunother. 2006 May-Jun; 29(3):274-83. View in: PubMed

. 131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer Cancer Biother Radiopharm. 2006 Feb; 21(1):5-14. View in: PubMed

. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy Clin Cancer Res. 2005 Dec 01; 11(23):8492-502. View in: PubMed

. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas Clin Cancer Res. 2005 Aug 15; 11(16):5971-80. View in: PubMed

. NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy Clin Cancer Res. 2005 Apr 15; 11(8):3084-93. View in: PubMed

. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer J Clin Oncol. 2005 Mar 01; 23(7):1538-47. View in: PubMed

. chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumors Hybrid Hybridomics. 2004 Feb; 23(1):1-10. View in: PubMed

. Monoclonal LYM-1 antibody-dependent cytolysis by human neutrophils exposed to GM-CSF: auto-regulation of target cell attack by cathepsin G J Leukoc Biol. 2004 Jan; 75(1):99-105. View in: PubMed

. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion Cancer Res. 2003 Dec 01; 63(23):8384-92. View in: PubMed

. Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody Cancer Biother Radiopharm. 2003 Dec; 18(6):931-40. View in: PubMed

. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis Cancer Res. 2003 Aug 15; 63(16):5046-53. View in: PubMed

. Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies Hybrid Hybridomics. 2003 Aug; 22(4):197-207. View in: PubMed

. LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors J Immunother. 2003 Jul-Aug; 26(4):320-31. View in: PubMed

. Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity Blood. 2003 Jun 15; 101(12):4853-61. View in: PubMed

. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT) Cancer Biother Radiopharm. 2003 Jun; 18(3):339-53. View in: PubMed

. Identification of a protein fragment of interleukin 2 responsible for vasopermeability J Natl Cancer Inst. 2003 May 21; 95(10):741-9. View in: PubMed

. Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors Hybrid Hybridomics. 2003 Feb; 22(1):1-9. View in: PubMed

. Generation of human interferon gamma and tumor Necrosis factor alpha chimeric TNT-3 fusion proteins Hybrid Hybridomics. 2002 Dec; 21(6):421-32. View in: PubMed

. Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin Cancer Biother Radiopharm. 2002 Aug; 17(4):359-70. View in: PubMed

. Newly established clear cell sarcoma (malignant melanoma of soft parts) cell line expressing melanoma-associated Melan-A antigen and overexpressing C-MYC oncogene Cancer Genet Cytogenet. 2002 May; 135(1):48-56. View in: PubMed

. Stable, genetically engineered F(ab')(2) fragments of chimeric TNT-3 expressed in mammalian cells Hybrid Hybridomics. 2002 Feb; 21(1):11-8. View in: PubMed

Powered bySC CTSI